AFREZZA is the New and Improved Inhalable Insulin for Diabetes

 

 

Coming soon to a pharmacy near you: AFREZZA, a new fast-acting form of inhaled insulin. According to recent studies, AFREZZA , will provide "glycemic control similar to standard insulin treatments with less risk of hypoglycemia and weight gain." Still waiting for FDA approval,  it also appears that AFREZZA will have a  lower risk of causing lung problems than Exubera, the first inhalable insulin on the market.

"AFREZZA is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, AFREZZA looks like the insulin that's normally in a person's body," said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of AFREZZA.

It is intended for use at mealtimes to control rapid rises in blood sugar that occur after meals in people with diabetes. The idea of an inhaled insulin appeals to diabetics who must use insulin every time they eat.

For information on diabetes supplies or insulin pumps, click here!

Now You Can Blame Your Big Belly and Diabetes on Bacteria!

New research is adding another reason why some people have large waistlines. Scientists say that excessive bacteria in the stomach caused by a lack of the TLR5 (Toll-Like Receptor 5) protein may be the culprit.

TLR5 guards against an overgrowth of bacteria in the intestines. If you remove TLR5, the intestines will be overgrown with an excessive amount of pathogens.  Inflammation will occur making the cells less sensitive to insulin.  And, If the cells become resistant to insulin, the glucose  will continue to circulate, causing high blood sugar and type 2 diabetes.

Recently, it has been discovered that probiotics, also known as “healthy” bacteria, can manipulate the balance of the microflora in the intestine by reducing the growth of “harmful” bacteria. and therefore may play a role in fighting obesity and controlling inflammation.